Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Truist Financial

Truist Financial reaffirmed their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $1,200.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. Royal Bank of Canada reaffirmed an outperform rating and set a $1,282.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 17th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a buy rating in a research note on Friday, August 2nd. Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an overweight rating in a research report on Friday, August 23rd. Finally, Cantor Fitzgerald reiterated a neutral rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,039.96 on Tuesday. The company has a 50 day moving average price of $1,129.87 and a 200-day moving average price of $1,033.99. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,211.20. The firm has a market cap of $114.59 billion, a price-to-earnings ratio of 30.72, a price-to-earnings-growth ratio of 3.72 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the company earned $8.79 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold 9,270 shares of company stock valued at $10,695,833 over the last 90 days. 7.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of REGN. Global Assets Advisory LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $339,594,000. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares in the last quarter. First Trust Advisors LP lifted its holdings in Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares in the last quarter. Finally, TD Asset Management Inc raised its position in shares of Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after acquiring an additional 166,998 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.